Pharmacotherapy in Children and Adolescents With Pervasive Developmental Disorders
Scahill L, Koenig K. Pharmacotherapy in Children and Adolescents With Pervasive Developmental Disorders. Journal Of Child And Adolescent Psychiatric Nursing 1999, 12: 41-43. PMID: 10347430, DOI: 10.1111/j.1744-6171.1999.tb00040.x.Peer-Reviewed Original ResearchConceptsSide effectsNeuroleptic medicationAtypical neurolepticsLong-term side effectsNewer atypical neurolepticsRecurrent side effectsSerotonin reuptake inhibitorsExtrapyramidal side effectsUntoward side effectsLowest possible doseCourse of treatmentTreatment of childrenSevere behavioral difficultiesSelf-injurious behaviorMedication withdrawalReuptake inhibitorsMedication doseClinical benefitTraditional neurolepticsAbnormal movementsPossible doseTreatment planBaseline measurementsDepressed moodWeight gainOpen-Label Quetiapine in the Treatment of Children and Adolescents with Autistic Disorder
Martin A, Koenig K, Scahill L, Bregman J. Open-Label Quetiapine in the Treatment of Children and Adolescents with Autistic Disorder. Journal Of Child And Adolescent Psychopharmacology 1999, 9: 99-107. PMID: 10461820, DOI: 10.1089/cap.1999.9.99.Peer-Reviewed Original ResearchConceptsClinical Global Impression ScaleTreatment of childrenSide effectsAutistic disorderOpen-label trialShort-term safetyWeeks of treatmentGlobal Impression ScaleGlobal improvement itemSignificant side effectsSerious side effectsDSM-IV criteriaFurther dose increasesLack of responseMean ageImpression ScalePossible seizuresMale subjectsWeight gainBehavioral activationFourth weekQuetiapine fumarateDose increaseClinical populationsWeeks